Literature DB >> 28693267

Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics.

Haipeng Wang1, Shengjian Jin1, Huiling Lu2, Sisi Mi2, Wenhua Shao2, Xiaoxv Zuo1, Huangyi Yin2, Sien Zeng2, Fumio Shimamoto3,4, Guangying Qi2,3.   

Abstract

Survivin is a bifunctional protein that suppresses apoptosis and regulates cell division, and is highly expressed in various cancer types. Mucins are high-molecular-weight, heavily glycosylated proteins. In the present study, the association between survivin, mucin 2 (MUC2) and MUC5 expression, and the clinicopathological features of colorectal cancer (CRC) were investigated. The immunohistochemistry and western blotting results demonstrated that survivin was highly expressed in CRC tissues and rarely expressed in normal colon tissues. Moreover, the overexpression of survivin and MUC5 was strongly associated with lymph node metastasis, poor cellular differentiation, advanced tumor stage and a poor prognosis in CRC. By contrast, low expression of MUC2 was significantly associated with lymph node metastasis, poor cellular differentiation and an advanced tumor stage in CRC. The results of the present study suggest that survivin, MUC2 and MUC5 levels may be associated with tumor progression and could be used to aid the early diagnosis and clinical characterization of CRC.

Entities:  

Keywords:  colorectal cancer; mucin 2; mucin 5; survivin

Year:  2017        PMID: 28693267      PMCID: PMC5494796          DOI: 10.3892/ol.2017.6218

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  MUC-2 human small intestinal mucin gene structure. Repeated arrays and polymorphism.

Authors:  N W Toribara; J R Gum; P J Culhane; R E Lagace; J W Hicks; G M Petersen; Y S Kim
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

2.  p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival.

Authors:  G Lanza; I Maestri; A Dubini; R Gafa; A Santini; S Ferretti; L Cavazzini
Journal:  Am J Clin Pathol       Date:  1996-05       Impact factor: 2.493

3.  Immunohistochemical staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in hyperplastic polyps, serrated adenomas, and traditional adenomas of the colorectum.

Authors:  A E Biemer-Hüttmann; M D Walsh; M A McGuckin; Y Ajioka; H Watanabe; B A Leggett; J R Jass
Journal:  J Histochem Cytochem       Date:  1999-08       Impact factor: 2.479

4.  Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.

Authors:  Masahide Ikeguchi; Tsuyoshi Ueta; Yoshiaki Yamane; Yasuaki Hirooka; Nobuaki Kaibara
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

5.  Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis.

Authors:  Rodrigo Oliva Perez; Bárbara Helou Bresciani; Cláudio Bresciani; Igor Proscurshim; Desiderio Kiss; Joaquim Gama-Rodrigues; Diego Daniel Pereira; Viviane Rawet; Ivan Cecconnello; Angelita Habr-Gama
Journal:  Int J Colorectal Dis       Date:  2008-05-06       Impact factor: 2.571

6.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

7.  Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1.

Authors:  Michaël Perrais; Pascal Pigny; Marie-Christine Copin; Jean-Pierre Aubert; Isabelle Van Seuningen
Journal:  J Biol Chem       Date:  2002-06-19       Impact factor: 5.157

Review 8.  Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases.

Authors:  Mahefatiana Andrianifahanana; Nicolas Moniaux; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2006-01-27

9.  [Expression of type 1 and type 2 mucins in colonic epithelial tumors].

Authors:  L E Gurevich; I A Kazantseva; N A Korsakova; P V Tsar'kov; L O Polishchuk
Journal:  Arkh Patol       Date:  2007 Mar-Apr

10.  Incidence of colorectal cancer in Poland in 1999-2008.

Authors:  Alicja Klimczak; Bogumiła Kempińska-Mirosławska; Michał Mik; Lukasz Dziki; Adam Dziki
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

View more
  9 in total

Review 1.  Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Authors:  Taxiarchis Konstantinos Nikolouzakis; Loukia Vassilopoulou; Persefoni Fragkiadaki; Theodoros Mariolis Sapsakos; Georgios Z Papadakis; Demetrios A Spandidos; Aristides M Tsatsakis; John Tsiaoussis
Journal:  Oncol Rep       Date:  2018-03-21       Impact factor: 4.136

Review 2.  Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Libin Yin; Yuyang Lin; Chenguang Li; Tao Liu; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2018-06-05       Impact factor: 2.260

3.  Loss of mismatch repair signaling impairs the WNT-bone morphogenetic protein crosstalk and the colonic homeostasis.

Authors:  Katrine Nørgaard; Carolin Müller; Nadja Christensen; María L Chiloeches; Cesilie L Madsen; Sabine S Nielsen; Tine E Thingholm; Antoaneta Belcheva
Journal:  J Mol Cell Biol       Date:  2020-07-03       Impact factor: 6.216

Review 4.  Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Tao Liu; Libin Yin; Chenyao Li; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2019-12-20       Impact factor: 2.260

5.  Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data.

Authors:  Bernhard Blank-Landeshammer; Vincent R Richard; Georgia Mitsa; Maud Marques; André LeBlanc; Laxmikanth Kollipara; Ingo Feldmann; Mathilde Couetoux du Tertre; Karen Gambaro; Suzan McNamara; Alan Spatz; René P Zahedi; Albert Sickmann; Gerald Batist; Christoph H Borchers
Journal:  Cancers (Basel)       Date:  2019-12-01       Impact factor: 6.639

6.  Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer.

Authors:  Sebastian Dwertmann Rico; Doris Höflmayer; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Christina Möller-Koop; Daniel Perez; Jakob R Izbicki; Michael Neipp; Hamid Mofid; Hannes Lárusson; Thies Daniels; Christoph Isbert; Stephan Coerper; Daniel Ditterich; Holger Rupprecht; Albert Goetz; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Patrick Lebok; Eike Burandt; Till Krech; Andreas H Marx
Journal:  Med Mol Morphol       Date:  2020-12-29       Impact factor: 2.309

7.  A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma.

Authors:  Pablo Azcue; David Guerrero Setas; Ignacio Encío; Berta Ibáñez-Beroiz; María Mercado; Ruth Vera; María Luisa Gómez-Dorronsoro
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

8.  Low expression of MUC2 is associated with longer disease-free survival in patients with colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Shabnum Sultana; Wafaey Gomaa
Journal:  Saudi J Gastroenterol       Date:  2019 Jan-Feb       Impact factor: 2.485

9.  MUC1 and MUC5AC implication in Tunisian colorectal cancer patients

Authors:  Meriam Hazgui; Marwa Weslati; Rahma Boughriba; Donia Ounissi; Dhouha Bacha; Saadia Bouraoui
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.